Sarepta Therapeutics, Inc.
SRPT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000873303
No open-market purchases or sales by Sarepta Therapeutics, Inc. insiders were filed in the last 90 days; 323 institutions reported holding it in 13F filings for Q2 2026, worth $1.93B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Sarepta Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 376
- +44 vs. Q2 2022
- Shares held
- 78.2M
- +4.86M (+6.6%) vs. Q2 2022
- Total value
- $8.65B
- +$3.15B (+57.2%) vs. Q2 2022
- New holders
- 80
- 121 more added
- Sold out
- 36
- 115 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRPT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 323 | $1.93B |
| Q1 2026 | 345 | $2.24B |
| Q4 2025 | 348 | $2.01B |
| Q3 2025 | 320 | $1.67B |
| Q2 2025 | 363 | $1.42B |
| Q1 2025 | 431 | $5.56B |
| Q4 2024 | 466 | $10.7B |
| Q3 2024 | 459 | $10.8B |
| Q2 2024 | 485 | $14.0B |
| Q1 2024 | 415 | $10.8B |
| Q4 2023 | 396 | $7.92B |
| Q3 2023 | 395 | $10.1B |
| Q2 2023 | 405 | $9.38B |
| Q1 2023 | 427 | $11.2B |
| Q4 2022 | 413 | $10.2B |
| Q3 2022 | 376 | $8.65B |
| Q2 2022 | 333 | $5.50B |
| Q1 2022 | 328 | $5.71B |
| Q4 2021 | 344 | $6.48B |
| Q3 2021 | 308 | $6.08B |
| Q2 2021 | 332 | $5.04B |
| Q1 2021 | 367 | $4.97B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Sarepta Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gabelli Funds LLC | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| Banque Cantonale Vaudoise | 0 | $0 | 0.00% | −467−100.0% | Sold out |
| Elequin Capital LP | 0 | $0 | 0.00% | −331−100.0% | Sold out |
| Sterling Investment Advisors, Ltd. | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Howe & Rusling Inc | 0 | $0 | 0.00% | −149−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −118−100.0% | Sold out |
| Atlas Capital Advisors LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Patriot Financial Group Insurance Agency, LLC | 0 | $0 | 0.00% | −70−100.0% | Sold out |
| Fairfield, Bush & Co. | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Exane Derivatives | – | – | – | – | Not filed |